Fluxion Biosciences Appoints Genetracer Biotech of Spain As an Isoflux Liquid Biopsy Certified Service Provider

SAN FRANCISCO, Feb. 27, 2017 /PRNewswire/ -- Fluxion Biosciences announced today that Genetracer Biotech of Santander, Spain has been appointed as a Certified Service Provider for Fluxion's IsoFlux CTC Liquid Biopsy System. The IsoFlux system will be used in Genetracer Biotech's novel liquid biopsy workflows for detection of mutations relevant to lung and colon cancer, with plans to move to other cancers as additional assays are developed. The laboratory is utilizing Fluxion's IsoFlux System to isolate, recover, and analyze CTCs (circulating tumor cells) from routine blood samples.

Liquid biopsies offer the potential to improve treatment of cancer by providing an affordable, non-invasive diagnostic. Fluxion's technologies include the IsoFlux system for high-sensitivity detection of cancer cells from a routine blood draw, and the Spotlight 59 NGS Oncology Panel for ultra-sensitive mutation detection of CTCs and ctDNA (circulating tumor DNA) isolated from routine blood samples. These solutions allow testing for a broad range of cancer biomarkers that will help guide treatment decisions using an emerging class of precision cancer therapies.

As a Certified Service Provider, Genetracer Biotech will provide liquid biopsy services supporting cancer research centers and bio-pharmaceutical companies. Additionally, Genetracer will participate in Fluxion's upcoming liquid biopsy lung cancer clinical study.  The study is aimed at improving lung cancer diagnostics by providing early stratification of high risk patients.

"We are delighted to partner with Genetracer Biotech," said Dr. Cristian Ionescu-Zanetti, Fluxion's CTO. "Genetracer is a leader in the development of tests for precision medicine, and we are honored to be working with them. We look forward to pioneering new liquid biopsy tests with Genetracer that lead to dramatically improved patient outcomes."

About Fluxion Biosciences
Fluxion's pioneering liquid biopsy technologies include the IsoFlux CTC Liquid Biopsy System and the Spotlight 59 NGS Oncology Panel for ultra-sensitive mutation detection from CTCs and ctDNA. Fluxion's technologies are used globally by leading cancer centers developing new tests for early cancer detection and patient monitoring. For more information about Fluxion Biosciences' liquid biopsy capabilities, visit http://isoflux.fluxionbio.com.

About Genetracer Biotech
Genetracer Biotech is a European SME pioneering in Liquid Biopsy and Next Generation Sequencing (NGS). DECODER (http://decodergentest.com/en/#) is the first noninvasive blood test that delivers high quality enrichment of CTCs and ctDNA using the advantages of the IsoFlux CTC Liquid Biopsy System and NGS. The ability to detect and quantify tumor mutations has proven effective in tracking tumor dynamics in real time. DECODER may influence clinical outcome and help to understand the dynamics of cancer evolution. With Decoder by Genetracer be a step ahead.

Contacts:

Fluxion Biosciences
Jeff Jensen
email: [email protected]
+1 650-241-4777

Genetracer Biotech
Edificio IBBTEC, en el Parque Científico Tecnológico de Cantabria
c/ Albert Einstein 22 – 39011 Santander. Spain.
TEL. +34 942 266 318
email: [email protected]

SOURCE Fluxion Biosciences Inc.

Related Links

http://fluxionbio.com